Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations
Authors:
- Dieter KoeberleDKDieter Koeberle
- Hans-Joerg SennHSHans-Joerg Senn
- 31 January 2007
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (1) , 46-52
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006
- Adjuvant chemotherapy in 2005: Standards and beyondThe Breast, 2005
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005Annals of Oncology, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancerAnnals of Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- S23 Adjuvant Endocrine Therapies for Pre/PerimenopausalWomenThe Breast, 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- Impact of Formal Continuing Medical EducationJAMA, 1999
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998